<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>18247187</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Linazasoro, G</dc:author>
<dc:description xml:lang="en">Determining the point at which drug therapy with a dopaminergic agent should begin in a patient with early Parkinson disease is controversial. The current trend favors not indicating any drug until functional disability is present. However, the evolution demonstrated by patients included in different clinical trials indicates that delaying dopaminergic treatment is associated with worst outcome. In addition, there are other experimental and clinical data that support this idea. On the other side of the argument is the possibility that early use of drugs may inducing adverse effects in non-disabled patients.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2008 Jun </dc:date>
<dc:title xml:lang="es">Inicio de la terapia dopamin√©rgica en la enfermedad de Parkinson: seis buenas razones para no retrasarlo.</dc:title>
<dc:title xml:lang="en">[Onset of dopaminergic therapy in Parkinson's disease: six good reasons not to delay it].</dc:title>
<dc:publisher>Neurologia (Barcelona, Spain)</dc:publisher>
</metadata>
</record>
</pubmed-document>
